Sugi Predict

Sugi Predict / Compounds / SCHEMBL344966

SCHEMBL344966

SCHEMBL344966

CC(CCO)(CCO)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.43
▸ TAAR1 Q96RJ0 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ESR1 P03372 2/20 0.41
▸ ESR2 Q92731 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ RIPK1 Q13546 2/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9513410 0.91 CYP2C19 (0.50) CYP2C19HIF1AALDH1A1TAAR1ALOX15
SCHEMBL5571409 0.89 CYP2C19 (0.48) CYP2C19HIF1AALDH1A1TAAR1ALOX15
SCHEMBL6345647 0.85 CYP2C19 (0.42) CYP2C19HIF1AALDH1A1TAAR1ALOX15
SCHEMBL14462729 0.85 RIPK1 (0.43) CYP2C19HIF1AALDH1A1TAAR1ALOX15
SCHEMBL3285591 0.84 CYP2C19 (0.49) CYP2C19HIF1AALDH1A1ESR1ESR2
SCHEMBL6344497 0.84 CYP2C19 (0.41) CYP2C19HIF1AALDH1A1TAAR1ALOX15
SCHEMBL3280203 0.82 CYP2C19 (0.47) CYP2C19HIF1AALDH1A1ESR1ESR2
SCHEMBL6346489 0.82 CYP2C19 (0.40) CYP2C19HIF1AALDH1A1TAAR1ALOX15
SCHEMBL6391549 0.82 ALDH1A1 (0.45) CYP2C19HIF1AALDH1A1TAAR1CYP3A4
SCHEMBL12945125 0.82 RIPK1 (0.41) CYP2C19HIF1AALDH1A1TAAR1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279518-A1 URETHANE RESIN-FORMING COMPOSITION, ADHESIVE AGENT, CURED PRODUCT, AND PRODUCTION METHOD FOR CURED PRODUCT TOSOH CORPORATION (JP) 2024-08-22 — — US disclosed
EP-4335885-A1 URETHANE RESIN-FORMING COMPOSITION, ADHESIVE AGENT, CURED PRODUCT, AND PRODUCTION METHOD FOR CURED PRODUCT Tosoh Corporation (JP) 2024-03-13 — — EP disclosed
CN-117500856-A Urethane resin-forming composition, adhesive, cured product, and method for producing cured product 东曹株式会社 2024-02-02 — — CN disclosed
WO-2022260107-A1 URETHANE RESIN-FORMING COMPOSITION, ADHESIVE AGENT, CURED PRODUCT, AND PRODUCTION METHOD FOR CURED PRODUCT 東ソー株式会社 2022-12-15 — — WO disclosed
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 — — US disclosed
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 — — US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 — — US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 — — US disclosed
US-20170369483-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2017-12-28 — — US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 — — US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 — — US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 — — US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 — — US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 — — US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 — — US disclosed
US-20060111351-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2006-05-25 — — US disclosed
WO-2005112925-A1 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2005-12-01 — — WO disclosed
US-20050137193-A1 Aryl sulfonamides CHEMOCENTREYX 2005-06-23 — — US disclosed
EP-0302516-B1 Optical article made of amorphous thermoplastic polyester resin MITSUBISHI RAYON CO (JP) 1993-12-15 — — EP disclosed
EP-0302516-A2 Optical article made of amorphous thermoplastic polyester resin MITSUBISHI RAYON CO., LTD. (JP) 1989-02-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137193-A1 Aryl sulfonamides CCR9, CCR1, CCR2 CYP2C19 1194/4885HIF1A 2220/4885ALDH1A1 1655/4885
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 CYP2C19 1194/4885HIF1A 2220/4885ALDH1A1 1655/4885
US-20060111351-A1 Aryl sulfonamides CCR9, CCR1, CCR2 CYP2C19 1194/4885HIF1A 2220/4885ALDH1A1 1655/4885
US-20170369483-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 CYP2C19 1194/4885HIF1A 2220/4885ALDH1A1 1655/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 CYP2C19 1194/4885HIF1A 2220/4885ALDH1A1 1655/4885
US-20090163498-A1 Aryl Sulfonamides CCR9, CCR1, CCR2 CYP2C19 1194/4885HIF1A 2220/4885ALDH1A1 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.